Avacta Group Plc - notizie pubblicate 142 - letture 4.954
AVACTA GROUP PLC
Full Year Results
The text version of this document is not available. you can access the original document here. attachments original link permalink disclaimer avacta group plc published this conten ...
AVACTA GROUP PLC
Results for the Year Ended 31 December 2023
The information contained within this announcement is deemed by the company to constitute inside information as stipulated under the market abuse regulations (eu) no. 596/2014 as i ...
AVACTA GROUP PLC
Results for the Year Ended 31 December 2023 – Presentation deck
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer avacta group plc pub ...
AVACTA GROUP PLC
Preliminary Results for the Year Ended 31 December 2023
Avacta appoints new chief executive officer christina coughlin, md phd clinical proof-of-concept demonstrated for avacta's lead programme ava6000 and proof-of-mechanism for the pre ...
AVACTA GROUP PLC
Christina Coughlin, MD, PhD, appointed Chief Executive Officer of Avacta Group
Dr. coughlin has served as a director since 2022, assuming the role of head of research and development in february 2024, driving the development of the pre|cision™ platform appo ...
AVACTA GROUP PLC
R&D Spotlight series – Episode 2
In the second episode of our r&d spotlight series we are fast forwarding into the clinic and talking to two members of the avacta translational medicine team. attachments origi ...
AVACTA GROUP PLC
Block Listing Application to AIM
The text version of this document is not available. you can access the original document here. attachments original link permalink disclaimer avacta group plc published this conten ...
AVACTA GROUP PLC
Block Listing Application to AIM
Avacta group plc (aim: avct), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics announces application has been made to aim for a block ...
AVACTA GROUP PLC
Notice of Results
Investor presentation via investor meet company avacta group plc (aim: avct), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, will ...
AVACTA GROUP PLC
Issue of Equity and Total Voting Rights
Avacta group plc (aim: avct), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics today announces it has issued and allotted a total of ...
AVACTA GROUP PLC
Issue of Equity and Total Voting Rights
The text version of this document is not available. you can access the original document here. attachments original link permalink disclaimer avacta group plc published this conten ...
AVACTA GROUP PLC
Avacta Therapeutics Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 at the AACR Annual Meeting Demonstrating Clinical Proof-of-Concept Showing Multiple Patient Responses
Ava6000 delivers high concentrations of doxorubicin to the tumor microenvironment ("tme") relative to plasma, resulting in significant antitumor activity in patients whos ...
AVACTA GROUP PLC
Avacta Reports Data at the AACR Annual Meeting
The text version of this document is not available. you can access the original document here. attachments original link permalink disclaimer avacta group plc published this conten ...
AVACTA GROUP PLC
AVA6000 Abstract Release by AACR and Full Presentation Update
Avacta group plc (aim: avct), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that the abstract of the poster to be ...
AVACTA GROUP PLC
Glossary
Glossary fap - fibroblast activation protein tme - tumour micro environnent prep - prolyl endopeptidase - a protein coding gene hek- human embryonic kidney hek model - human embryo ...
Per i consulenti finanziari
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti